CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

benzinga.com/markets/earnings/25/11/48810348/cormedix-q3-profit-soars-as-defencath-dialysis-demand-exceeds-expectations

CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents.
Sales reached $104.27 million, a jump from $11.5 million a year ago, beating the consensus of $86.02 million.
Net revenue of $104.3 million and pro forma net…

This story appeared on benzinga.com, 2025-11-12 16:49:31.
The Entire Business World on a Single Page. Free to Use →